Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple device accurately track muscle paralysis in the ICU?

NCT ID NCT07741851

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study evaluates how reliably a device monitors neuromuscular blockade (temporary muscle paralysis) in adult intensive care patients. The goal is to see if the device's readings match the expected response in patients without paralysis, and whether using it helps avoid complications like breathing difficulties. Researchers will compare different stimulation methods and track safety over 24-hour periods. The findings could improve how ICU teams monitor and manage muscle relaxants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
neuromuscular blockade monitoring using the TOFscan Idmed device
What this could lead to
If reliable, this monitoring method could help ICU teams better manage muscle paralysis, reducing risks and improving patient safety.
What could go wrong
The study is observational and may not capture all clinical variations. Device readings might not always match real conditions, and results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients * Patients admitted to the intensive care unit who have been receiving neuromuscular blocking agents for at least 24 hours during their stay - Consent obtained from the patient or emergency consent obtained from family members * Patients covered by the French social security system, regardless of the specific plan Exclusion Criteria: * Patients who have already been exposed to prolonged neuromuscular blockade or who have been receiving continuous neuromuscular blockade for less than 24 hours * Allergy to neuromuscular blocking agents * Patients with a neurological condition that alters the interpretation of neuromuscular blockade or contraindicates the use of neuromuscular blocking agents * Patients enrolled in an interventional study * Patients who object to the collection of their medical data for this study * Patients under the age of 18 * Patients deprived of their liberty, under guardianship, or under conservatorship * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuromuscular blockade monitoring are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal Aix-Pertuis

    RECRUITING

    Aix-en-Provence, 13090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.